Sonara Health Granted Patent For Take-Home Methadone Monitoring System

Revolutionary Monitoring System's Tamper-Evident Label Allows People To More Safely Consume Methadone From Home, Eliminating Daily Clinic Visits

Sonara Health has been granted a U.S. patent for creating a tamper-evident label that facilitates the safe consumption of methadone at home to treat opioid use disorder and fight America’s opioid crisis.

Sonara Health’s remote medication monitoring system includes a tamper-evident label, a patient-facing web application to guide the patient’s daily consumption of methadone at home and a clinician-facing web application to remotely, asynchronously, observe patients dosing. The Sonara remote medication monitoring system helps eliminate the need for patients to visit a clinic every day, which is often a barrier for people who live far away from clinics or who have jobs and family obligations.

Methadone is among the most effective medications approved by the FDA to treat opioid use disorder.

“In a world where we send billionaires to space in reusable rockets, I thought we ought to be able to create a solution that helps patients with opioid use disorder to get their daily medication in a way that does not disrupt their daily lives, all while preserving the safety and efficacy of a proven delivery system,” said Michael Giles, M.D., and CEO of Sonara Health.

The Mark Cuban-backed health-tech company was designed to improve patient-provider trust and promote access to take-home methadone for opioid treatment programs and their patients. Sonara’s mission is to end the opioid epidemic. Staggering data from the CDC showed over 100,000 people died from drug overdoses last year and about two-thirds of those deaths involved fentanyl or another synthetic opioid.

The Sonara medication monitoring system is simple. The patient scans the QR code on the methadone bottle with their smartphone and follows the steps provided for dosing-at-home. Once scanned and opened, the QR code is voided and the label indicates that it has been opened. The phone’s camera then turns on and a video stream of the patient drinking the methadone is uploaded to the clinician-facing application for the care team to review and ensure proper medication handling.

Early adopters of Sonara include the following opioid treatment programs:

BayMark Health Services, Inc.

BAART, Market Street, San Francisco, CA
BAART, Norwood, Sacramento, CA
HCRC, New Bedford, MA
RSONM, Five Points, Albuquerque, NM (coming soon)
RSONM, Roswell, NM (coming soon)
CODA, Inc.

CODA, Portland, OR
CODA, Seaside, OR
New Season Treatment Centers

Augusta Metro Treatment Center, Augusta, GA

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”